Biblio Discovery — Demo Discovery Service

33 hasil untuk "Joselle Cook"

Menampilkan 1–20 · 0,48 detik · RSS

  1. Artikel Jurnal

    Incidental Discovery of Multiorgan Extramedullary Plasmacytomas in the Setting of Newly Diagnosed Multiple Myeloma and Delayed Hemolytic Transfusion Reaction

    Joselle Cook; Steven Song; Anthony Ventimiglia dkk.

    Case Reports in Hematology, Vol. 2017 · 2017 · Inggris · DOAJ

    Extramedullary plasmacytomas (EMPs) are defined by the presence of clonal plasma cell proliferation outside of the bone marrow, portending an overall poor prognosis. This case highlights extramedullary plasmacytomas as an unusual presenting manifestation of multiple myeloma. Through incidental…

  2. Artikel Jurnal Teks lengkap

    Monoclonal Gammopathy of Clinical Significance (MGCS) and Related Disorders: A Review and the Role of Imaging

    Ahmed O. El Sadaney; Anika Dutta; Joselle Cook dkk.

    Diagnostics, Vol. 14 No. 17 · 2024 · Inggris · DOAJ Scopus

    The term monoclonal gammopathy of clinical significance (MGCS) refers to a group of symptomatic monoclonal gammopathies that do not meet the diagnostic criteria for malignant plasma cell disorders, such as multiple myeloma or Waldenström macroglobulinemia. These symptoms are attributable to the…

  3. Artikel Jurnal

    First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab

    Steven Song; Joselle Cook; Clive Goulbourne dkk.

    Case Reports in Cardiology, Vol. 2017 · 2017 · Inggris · DOAJ Scopus

    Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation. The potential for life-threatening hemorrhagic events with the use of NOACs has been highly debated since the effectiveness of reversal agents…

  4. Artikel Jurnal

    Oncolytic virotherapy – Forging its place in the immunomodulatory paradigm for Multiple Myeloma

    Joselle Cook, MD; Aldo A. Acosta-Medina, MD; Kah Whye Peng, PhD dkk.

    Cancer Treatment and Research Communications, Vol. 29 · 2021 · Inggris · DOAJ Scopus

    The treatment focus for multiple myeloma (MM) has recently pivoted towards immune modulating strategies, with T-cell redirection therapies currently at the forefront of drug development. Yet, despite this revolution in treatment, MM remains without a sustainable cure. At the same time, tremendous…

  5. Artikel Jurnal

    A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncology

    Rahma Warsame; Joselle Cook; Briant Fruth dkk.

    Contemporary Clinical Trials Communications, Vol. 29 · 2022 · Inggris · DOAJ Scopus

    Background: Clinicians have limited time during patient encounters which can result in patients' concerns not being addressed. This study's objective was to test whether an electronic patient-reported outcome quality of life tool (PROQOL) in which patients identify their primary concern during…

  6. Artikel Jurnal

    The ratio of brain to liver glucose activity and disease activity in multiple myeloma

    Sarah Dingli; Paul Rothweiler; Moritz Binder dkk.

    Blood Cancer Journal, Vol. 15 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Changes in metabolic activity in tumor cells is one of the hallmarks of cancer. Cancer cells exhibit the Warburg effect with high glucose consumption for their energy needs. This provides the basis for imaging using 18F-2-deoxy-D-glucose for positron emission tomography to assess tumor…

  7. Artikel Jurnal

    Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study

    Yoshito Nishimura; Thomas Habermann; Morie Gertz dkk.

    Blood Advances, Vol. 10 No. 5 · 2026 · Inggris · DOAJ Scopus

    Abstract: Castleman disease (CD) is a heterogeneous group of lymphoproliferative disorders anatomically classified by distribution (unicentric CD [UCD], oligocentric CD [oligoCD], or multicentric CD [MCD]). Human herpes virus 8–negative MCD is called idiopathic MCD (iMCD), which includes clinical…

  8. Artikel Jurnal

    Cumulative deficits frailty index and relationship status predict survival in multiple myeloma

    Nadine Abdallah; Paul Dizona; Amanika Kumar dkk.

    Blood Advances, Vol. 9 No. 5 · 2025 · Inggris · DOAJ Scopus

    Abstract: Several tools have been proposed for assessing frailty in multiple myeloma (MM), but most are based on clinical trial data sets. There are also limited data on the association between frailty and patient-reported outcomes and on the prognostic value of social determinants of health. This…

  9. Artikel Jurnal

    Mode of progression in smoldering multiple myeloma: a study of 406 patients

    Nadine H. Abdallah; Arjun Lakshman; Shaji K. Kumar dkk.

    Blood Cancer Journal, Vol. 14 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to multiple myeloma (MM). We aimed to describe the myeloma-defining events (MDEs) and clinical presentations…

  10. Artikel Jurnal

    Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma

    Linda B. Baughn; Erik Jessen; Neeraj Sharma dkk.

    Blood Cancer Journal, Vol. 13 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Multiple myeloma (MM) remains an incurable plasma cell (PC) malignancy. Although it is known that MM tumor cells display extensive intratumoral genetic heterogeneity, an integrated map of the tumor proteomic landscape has not been comprehensively evaluated. We evaluated 49 primary tumor…

  11. Artikel Jurnal

    From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis

    Eli Muchtar; Angela Dispenzieri; Francis K. Buadi dkk.

    Blood Advances, Vol. 9 No. 16 · 2025 · Inggris · DOAJ Scopus

    Abstract: This retrospective analysis examined 15 years of autologous stem cell transplantation (ASCT) for light chain (AL) amyloidosis at the Mayo Clinic (2010-2024). We aimed to assess ASCT utilization trends, factors influencing practice changes, and current indications amid newer therapies…

  12. Artikel Jurnal

    Long-term outcomes of allogeneic stem cell transplant in multiple myeloma

    Walker M. Schmidt; Nirosha D. Perera; Francis K. Buadi dkk.

    Blood Cancer Journal, Vol. 13 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Allogeneic stem cell transplant (allo SCT) for multiple myeloma (MM) is potentially curative in some, while toxic in many others. We retrospectively analyzed 85 patients diagnosed with MM who underwent allo SCT as frontline or salvage therapy between 2000 and 2022 at Mayo Clinic Rochester…

  13. Artikel Jurnal

    Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response

    Matthew J. Rees; Susan Geyer; Binoy Yohannan dkk.

    Haematologica, Vol. 999 No. 1 · 2025 · Inggris · DOAJ Scopus

    Cardiac response (CarR) is associated with survival in AL amyloidosis, but substantial variation exists in response kinetics. We investigated variables associated with deep CarRs to characterize the factors that govern organ recovery. Retrospective study of newly-diagnosed AL amyloidosis patients…

  14. Artikel Jurnal

    CAR T-cell therapy outcomes in plasma cell leukemia

    Melinda Tan; Joselle Cook; Wilson I. Gonsalves dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 1 · 2026 · Inggris · DOAJ

    Abstract: Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder with poor outcomes. We retrospectively evaluated 26 patients with primary PCL (n = 21) or secondary PCL (n = 5) treated with anti–B-cell maturation antigen–directed chimeric antigen receptor T-cell (CAR-T…

  15. Artikel Jurnal

    Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis

    Elham Askari; Angela Dispenzieri; Francis K. Buadi dkk.

    Blood Cancer Journal, Vol. 15 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Uniform assessment of response to treatment is crucial to managing multiple myeloma (MM) and developing new therapies. Measurement of monoclonal protein forms the cornerstone of disease assessment in MM. According to International Myeloma Working Group (IMWG) guidelines, serum-free light…